ACM
ABBV icon

Alpha Capital Management’s AbbVie ABBV Stock Holding History

Alpha Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.13M Buy
28,193
+66
+0.2% +$14.6K 0.89% 33
2025
Q4 		$6.43M Buy
28,127
+155
+0.6% +$35.3K 0.91% 38
2025
Q3 		$6.48M Sell
27,972
-518
-2% -$105K 1.03% 36
2025
Q2 		$5.29M Buy
28,490
+1,213
+4% +$225K 0.91% 42
2025
Q1 		$5.72M Sell
27,277
-364
-1% -$70.8K 1.09% 32
2024
Q4 		$4.91M Buy
27,641
+419
+2% +$77K 0.9% 38
2024
Q3 		$5.38M Sell
27,222
-504
-2% -$94.1K 1.01% 32
2024
Q2 		$4.76M Buy
27,726
+46
+0.2% +$7.62K 0.93% 35
2024
Q1 		$5.04M Sell
27,680
-1,709
-6% -$295K 0.98% 32
2023
Q4 		$4.55M Buy
29,389
+157
+0.5% +$22.9K 0.94% 35
2023
Q3 		$4.36M Sell
29,232
-1,569
-5% -$230K 1.02% 27
2023
Q2 		$4.98M Hold
30,801
– – 1.24% 22
2023
Q1 		$4.98M Hold
30,801
– – 1.24% 22
2022
Q4 		$4.98M Sell
30,801
-532
-2% -$81.6K 1.24% 22
2022
Q3 		$4.21M Buy
31,333
+439
+1% +$63K 1.11% 26
2022
Q2 		$4.73M Buy
30,894
+1,002
+3% +$153K 1.29% 20
2022
Q1 		$4.85M Buy
29,892
+267
+0.9% +$38.8K 1.05% 24
2021
Q4 		$4.01M Buy
29,625
+281
+1% +$33.2K 0.89% 38
2021
Q3 		$3.17M Buy
29,344
+897
+3% +$102K 0.75% 47
2021
Q2 		$3.2M Buy
28,447
+74
+0.3% +$8.33K 0.75% 43
2021
Q1 		$3.07M Buy
28,373
+670
+2% +$71.7K 0.78% 37
2020
Q4 		$2.97M Sell
27,703
-856
-3% -$82.3K 0.75% 37
2020
Q3 		$2.5M Buy
28,559
+325
+1% +$30.6K 0.72% 45
2020
Q2 		$2.77M Buy
+28,234
New +$2.49M 0.95% 35
2013
Q3 		– Sell
-23,267
Closed -$962K – 80
2013
Q2 		$962K Buy
+23,267
New +$1.02M 0.9% 47

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alpha Capital Management's ABBV Position: Q1 2026 in Review

Alpha Capital Management increased its AbbVie (ABBV) stake by 0.23% in Q1 2026, buying an estimated $14.6K and bringing the position to 28,193 shares worth $6.13M. The position accounts for 0.89% of the portfolio, ranked #33.

Alpha Capital Management first reported a position in ABBV in Q2 2013 and has held it in 25 quarters since. The position peaked at $6.48M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Alpha Capital Management held 28,193 shares of AbbVie worth $6.13M as of Q1 2026.
  • Alpha Capital Management bought 66 AbbVie shares in Q1 2026, an estimated $14.6K.
  • AbbVie made up 0.89% of Alpha Capital Management's portfolio in Q1 2026, its #33 holding.
  • Alpha Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 25 quarters since.
  • Alpha Capital Management's AbbVie position peaked at $6.48M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Alpha Capital Management's 13F filing for Q1 2026, filed 13 May 2026.